Chardan Capital Reduces Earnings Estimates for Korro Bio

Key Points

• Korro Bio's FY2025 earnings per share (EPS) estimates have been reduced to ($10.05) from the previous ($10.00) by Chardan Capital, which maintains a Buy rating and a $25.00 target price for the stock.
• The stock currently has a consensus rating of Buy among analysts, with an average target price of $86.83, despite recent target price reductions from several brokerages.
• Korro Bio's stock recently opened at $20.26 and has a market cap of $190.24 million, reflecting significant volatility with a 52-week low of $10.29 and high of $98.00.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities research analysts at Chardan Capital decreased their FY2025 EPS estimates for Korro Bio in a research report issued on Wednesday, August 13th. Chardan Capital analyst K. Nakae now expects that the company will earn ($10.05) per share for the year, down from their prior estimate of ($10.00). Chardan Capital currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. Chardan Capital also issued estimates for Korro Bio's FY2026 earnings at ($7.66) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($2.74) EPS for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The firm had revenue of $1.46 million for the quarter, compared to the consensus estimate of $0.41 million.

Several other equities research analysts have also recently commented on KRRO. HC Wainwright lowered their price target on shares of Korro Bio from $100.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Oppenheimer lowered their price target on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Cantor Fitzgerald upgraded shares of Korro Bio to a "strong-buy" rating in a research report on Tuesday, April 29th. Finally, Raymond James Financial lowered their price target on shares of Korro Bio from $153.00 to $147.00 and set a "strong-buy" rating for the company in a research report on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat.com, Korro Bio has a consensus rating of "Buy" and an average price target of $86.83.

Korro Bio Trading Down 2.5%

Shares of NASDAQ:KRRO traded down $0.51 during trading on Monday, hitting $20.04. 148,056 shares of the company's stock were exchanged, compared to its average volume of 128,850. Korro Bio has a 1-year low of $10.29 and a 1-year high of $98.00. The firm has a 50-day moving average price of $14.83 and a two-hundred day moving average price of $17.62. The firm has a market cap of $188.18 million, a P/E ratio of -2.06 and a beta of 2.51.

Institutional Trading of Korro Bio

A number of hedge funds have recently modified their holdings of KRRO. Quarry LP acquired a new position in shares of Korro Bio in the 1st quarter valued at approximately $35,000. Wells Fargo & Company MN grew its position in shares of Korro Bio by 32.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock valued at $129,000 after purchasing an additional 831 shares during the period. Deutsche Bank AG grew its position in shares of Korro Bio by 29.4% in the 4th quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock valued at $156,000 after purchasing an additional 935 shares during the period. Legal & General Group Plc grew its position in shares of Korro Bio by 664.1% in the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after purchasing an additional 3,759 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Korro Bio by 997.3% in the 4th quarter. California State Teachers Retirement System now owns 4,850 shares of the company's stock valued at $185,000 after purchasing an additional 4,408 shares during the period. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).